证券代码：301305 证券简称：朗坤环境 公告编号：2025-030 深圳市朗坤科技股份有限公司 关于召开2024年年度股东大会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或者重大遗漏。 根据《公司法》和《深圳市朗坤科技股份有限公司章程》（以下简称"《公 司章程》"）的有关规定，经深圳市朗坤科技股份有限公司（以下简称"公司"） 第三届董事会第二十二次会议审议通过，决定于 2025 年 5 月 16 日（星期五） 14:00 召开 2024 年年度股东大会，现将会议有关事项通知如下： 一、召开会议的基本情况 1. 股东大会届次：2024 年年度股东大会 2. 会议召集人：公司董事会 3. 会议召开的合法性、合规性：本次股东大会的召开符合有关法律、法规和《公 司章程》的有关规定。 4. 会议召开的日期、时间： （1）现场会议召开时间：2025 年 5 月 16 日 14:00 （2）网络投票时间：通过深圳证券交易所（以下简称"深交所"）交易系统进 行网络投票的具体时间为：2025 年 5 月 16 日的交易时间，即 9:15—9:25，9:30— 11:30 和 ...

证券代码：301305 证券简称：朗坤环境 公告编号：2025-016 深圳市朗坤科技股份有限公司 第三届监事会第十三次会议决议的公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或者重大遗漏。 一、监事会会议召开情况 深圳市朗坤科技股份有限公司（以下简称"公司"）第三届监事会第十三次 会议通知于 2025 年 4 月 12 日以电子邮件方式发出，会议于 2025 年 4 月 23 日 在公司会议室以现场结合通讯的方式召开。会议由监事会主席源晓燕女士主持， 应到监事 3 人，实到监事 3 人，公司董事会秘书严武军先生列席了会议。会议的 召集、召开和表决程序符合《公司法》等法律、法规和《公司章程》的有关规定。 二、监事会会议审议情况 1、审议通过《关于公司<2024 年年度报告>全文及其摘要的议案》 监事会认为：《2024 年年度报告》《2024 年年度报告摘要》的编制符合法 律、法规及《公司章程》等相关规定；公司 2024 年年度报告的内容和格式符合 中国证监会和深圳证券交易所的规定，报告内容真实、准确、完整地反映了公司 的实际情况，不存在任何虚假记载、误导性陈述或者重 ...

根据《公司法》《证券法》《上市公司股权激励管理办法》（以下简称"《管 理办法》"）《深圳证券交易所创业板股票上市规则》《深圳证券交易所创业板 上市公司自律监管指南第 1 号-业务办理》等有关法律、行政法规、规范性文件 以及《公司章程》的规定，公司监事会对《深圳市朗坤环境集团股份有限公司 2023 年限制性股票激励计划（修订稿）》（以下简称"本激励计划"）首次及预留授 予部分第一个归属期归属名单进行了核查，并发表核查意见如下： 本激励计划中有除 10 名激励对象因个人原因已离职以及 1 名激励对象因个 人原因放弃参与本激励计划，上述人员已不再具备激励对象资格；2 名激励对象 因 2024 年度个人层面绩效考核结果为不合格，不满足本期归属条件。除上述激 励对象外，本次拟归属的 89 名激励对象均符合本激励计划规定的激励对象范围， 具备《公司法》《证券法》等法律、法规和规范性文件及《公司章程》规定的任 职资格，符合《管理办法》等法律、法规和规范性文件规定的激励对象条件，其 作为公司本激励计划激励对象的主体资格合法、有效。 综上，公司监事会认为，本激励计划规定的首次及预留授予部分第一个归属 期归属条件已经成就，同意公 ...

证券代码：301305 证券简称：朗坤环境 公告编号：2025-015 深圳市朗坤科技股份有限公司 第三届董事会第二十二次会议决议的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或者重大遗漏。 一、董事会会议召开情况 深圳市朗坤科技股份有限公司（以下简称"公司"）第三届董事会第二十二 次会议通知于 2025 年 4 月 12 日以电子邮件方式发出，会议于 2025 年 4 月 23 日 在公司会议室以现场结合通讯的方式召开。会议由董事长陈建湘先生主持，应到 董事 7 人，实到董事 7 人。公司监事及高级管理人员列席了会议。会议的召集、 召开和表决程序符合《公司法》等法律、法规和《公司章程》的有关规定。 二、董事会会议审议情况 1、审议通过《关于公司<2024 年年度报告>全文及其摘要的议案》 公司出具的《2024 年年度报告》《2024 年年度报告摘要》符合法律法规、 行政法规、中国证监会和深圳证券交易所的规定，报告内容真实、准确、完整地 反映了公司 2024 年全年经营的实际情况，不存在任何虚假记载、误导性陈述或 者重大遗漏。 《2024 年年度报告》《2024 ...

关于公司2024年度利润分配方案的公告 证券代码：301305 证券简称：朗坤环境 公告编号：2025-019 深圳市朗坤科技股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或者重大遗漏。 一、审议程序 深圳市朗坤科技股份有限公司（以下简称"公司"）于 2025 年 4 月 23 日召 开第三届董事会第二十二次会议、第三届监事会第十三次会议，审议通过了《关 于公司 2024 年度利润分配方案的议案》。本议案尚需提交公司 2024 年年度股东 大会审议。 本次利润分配方案尚需提交公司 2024 年年度股东大会审议。 （二）是否可能触及其他风险警示情形及其具体原因 二、2024 年度利润分配方案 （一）利润分配方案的具体内容 经天健会计师事务所（特殊普通合伙）审计，公司 2024 年度实现归属于上 市公司股东的净利润为 215,543,277.64 元。提取 10%的法定盈余公积后，截至 2024 年 12 月 31 日，公司合并报表未分配利润为 1,119,403,172.31 元，母公司报 表未分配利润为 204,977,592.23 元。根据合并报表、母公司 ...

Financial Performance - The company's operating revenue for 2024 reached ¥1,791,038,381.87, representing a 2.18% increase compared to ¥1,752,883,083.75 in 2023[23]. - Net profit attributable to shareholders for 2024 was ¥215,543,277.64, a 20.51% increase from ¥178,855,243.12 in 2023[23]. - The net profit after deducting non-recurring gains and losses was ¥220,825,967.57, up 32.07% from ¥167,205,327.63 in 2023[23]. - Cash flow from operating activities significantly increased by 246.14% to ¥391,279,244.84 from ¥113,040,076.83 in 2023[23]. - Basic earnings per share for 2024 were ¥0.8907, an increase of 8.66% from ¥0.8197 in 2023[23]. - Total assets at the end of 2024 were ¥5,936,966,199.18, a slight decrease of 0.33% from ¥5,956,418,676.15 at the end of 2023[23]. - The net assets attributable to shareholders increased by 4.89% to ¥3,567,250,888.84 from ¥3,400,817,059.40 in 2023[23]. - The company reported a significant increase in cash flow from operations in Q1 2024, amounting to ¥152,458,017.58[25]. Strategic Development - The company has a comprehensive strategy for future development, although specific financial commitments are not guaranteed[4]. - The company is focused on expanding its market presence and exploring new technologies[3]. - The company is expanding its market presence through strategic partnerships and acquisitions in the environmental sector[15]. - The company aims to achieve international advanced levels in certain future industry sectors, supported by government initiatives to foster innovation and development[36]. - The company is actively involved in the research and development of human milk oligosaccharides (HMOs) for potential applications in the food and pharmaceutical industries[16]. - The company is exploring commercial opportunities in various sectors, including infant formula and health products, to expand the application of HMOs and drive revenue growth[63]. - The company is currently developing high-content LNnT and LNT products, which are expected to enhance its core competitiveness in the health sector[89]. Environmental and Technological Initiatives - The company is committed to sustainable development and has implemented various projects to enhance its ecological footprint[15]. - The company is involved in several biomass resource regeneration center projects, including those in Guangzhou and Shenzhen, aimed at waste classification and processing[15]. - The company has established multiple subsidiaries focused on biological resource recycling and environmental technology across various regions[15]. - The company is leveraging AI and high-throughput screening platforms to optimize HMO production strains, enhancing its competitive edge in synthetic biology[58]. - The company has established a biological manufacturing base with an annual production capacity of 1,000 tons of HMOs, with phase one (260 tons) expected to begin trial production in the first half of 2025 and phase two (740 tons) projected to be operational by 2026[54]. - The company is focused on maintaining compliance with regulatory standards set by national authorities, including the National Development and Reform Commission and the Ministry of Ecology and Environment[16]. Governance and Compliance - The annual report is confirmed to be accurate and complete by the board of directors and senior management[4]. - The report outlines the governance structure and responsibilities of the board and management[4]. - The company has a board of directors consisting of 7 members, including 3 independent directors, ensuring compliance with legal and regulatory requirements[150]. - The company maintains independence from its actual controller in terms of personnel, assets, business, and financial accounting systems, allowing for independent operation and risk management[149]. - The company has established a complete and independent asset structure, including land, factories, and equipment, with no legal disputes over these assets[159]. - The company has implemented a robust investor relations management system, enhancing transparency and communication with investors[155]. Market Opportunities and Challenges - The company is positioned to leverage the growing demand for biodiesel in the EU, where it is seen as a key solution to meet stringent emission reduction requirements[42]. - The domestic market for biodiesel is expanding, with applications in environmentally friendly materials and fuels, driven by updated national quality standards for diesel[43]. - The company faces risks related to rapid technological upgrades, which could impact its market position if not addressed[128]. - The company faces risks from fluctuations in the procurement prices of waste oils, which are influenced by market demand and commodity prices[141]. - The accounts receivable balance has been increasing, posing risks of liquidity shortages and bad debt losses if not managed effectively[142]. Research and Development - Research and development expenses increased by 39.54% to 84,732,722.56 CNY, driven by the company's focus on synthetic biology[88]. - The company has completed the strain modification research for 2'-fucosyllactose and 3-fucosyllactose, enhancing product competitiveness and sustainability[89]. - The company has established various R&D platforms, including AI and bioinformatics, to support the production of HMOs and foster innovation in synthetic biology[127]. - The company is committed to enhancing credit policies to improve sales and reduce bad debts, thereby increasing operational efficiency[140]. Human Resources and Training - The total number of employees at the end of the reporting period is 1,627, with 296 in the parent company and 1,331 in major subsidiaries[196]. - The professional composition includes 1,141 production personnel, 21 sales personnel, 141 technical personnel, 58 financial personnel, and 266 administrative personnel[196]. - The company founded Langkun University in 2021 to enhance employee skills and foster versatile talent through a diverse learning platform[199]. - Launched 6 sessions of "Langkun New Lion Training Camp" for new employees and elite recruits to quickly adapt to company culture and acquire basic business knowledge[200]. - Developed specialized training programs for professional staff in marketing, procurement, HR, finance, and technology, covering R&D technology, marketing enhancement, project construction, and operations[200]. Investment and Financial Management - The total amount of funds raised by the company is 1,537.54 million RMB, with a net amount of 1,424.99 million RMB[110]. - The total amount of raised funds utilized during the reporting period is 316.42 million RMB, including 30 million RMB for share repurchase and 130.71 million RMB for the organic waste resource processing project[110]. - The company plans to utilize the remaining raised funds for permanent working capital, amounting to 157 million RMB[110]. - The company has adjusted its investment projects, changing the focus from the R&D center to the construction of a biomass resource regeneration center in Fangshan District[113]. - The company aims to improve the efficiency of fundraising usage and optimize its financial structure by reallocating funds to support daily operations and business development[118].

Financial Performance - The company's revenue for Q1 2025 was ¥412,207,153.06, a decrease of 16.47% compared to ¥493,477,236.15 in the same period last year[5] - Net profit attributable to shareholders increased by 94.77% to ¥76,842,993.90 from ¥39,453,145.75 year-on-year[5] - Basic and diluted earnings per share rose by 97.28% to ¥0.3196 from ¥0.1620 in the same period last year[5] - Operating profit increased to ¥95,150,713.22, up from ¥45,019,532.92, showing a growth of 111.2%[21] - Net profit for the current period is ¥79,983,826.62, compared to ¥43,198,884.56 in the previous period, reflecting an increase of 84.9%[21] - The total comprehensive income for the period was CNY 79,983,826.62, compared to CNY 43,198,884.56 in the previous period, an increase of 84.9%[22] Cash Flow - The net cash flow from operating activities decreased by 21.31% to ¥119,968,984.45 compared to ¥152,458,017.58 in the previous year[5] - Cash inflows from operating activities totaled CNY 409,176,315.44, compared to CNY 514,198,099.43 in the previous period, a decline of 20.4%[25] - The net cash flow from investment activities was negative at -¥82,182,789.07, a decrease of 174.94% compared to the previous year, driven by increased project construction expenditures[9] - The cash and cash equivalents at the end of the period amounted to CNY 979,292,106.38, down from CNY 1,405,025,200.37, a decrease of 30.3%[26] - The company reported a cash outflow from financing activities of CNY -25,909,736.84, an improvement from CNY -65,752,968.18 in the previous period[26] Operating Costs and Expenses - The company's operating costs decreased by 33.02% to ¥253,574,167.95 from ¥378,590,426.71 year-on-year, attributed to product structure optimization[9] - Total operating costs decreased to ¥322,268,648.10 from ¥455,072,945.15, representing a reduction of 29.1%[21] - Research and development expenses decreased by 45.72% to ¥11,601,743.51 from ¥21,374,827.73 in the previous year, mainly due to the completion of certain R&D projects[9] - The income tax expense surged by 850.52% to ¥14,877,021.22 from ¥1,565,137.65 in the same period last year, primarily due to increased corporate income tax provisions[9] - The company paid CNY 22,867,275.68 in taxes, a decrease from CNY 39,222,151.10 in the previous period, reflecting a reduction of 41.6%[25] Shareholder Information - Total number of common shareholders at the end of the reporting period is 20,526[11] - The largest shareholder, Shenzhen Jianyin Wealth Investment Holdings Co., Ltd., holds 11.82% of shares, totaling 28,800,000 shares[11] - The top 10 shareholders collectively hold a significant portion of shares, with the first five shareholders accounting for approximately 42.38% of total shares[11] - The total number of restricted shares at the end of the period is 117,448,750, with no shares released during the current period[13] - The company maintains a strong relationship among major shareholders, indicating a unified action strategy[11] Product Development and Certifications - The company announced that its product 2'-fucosyllactose (2'-FL) has received Self-GRAS certification in the U.S.[14] - The company has ongoing product development, including the certification of lactose-N-tetraose (LNT) through Self-GRAS in the U.S.[15] - The company completed a share repurchase program, with details announced on March 3, 2025[15] - There were no changes in the number of shares lent or returned by major shareholders due to margin trading activities[12] - The company has a clear timeline for the release of restricted shares, with the first batch set to be released on November 25, 2026[13] Assets and Liabilities - Total assets at the end of the reporting period were ¥5,958,974,814.44, a slight increase of 0.37% from ¥5,936,966,199.18 at the end of the previous year[5] - Total liabilities decreased to ¥2,204,960,925.51 from ¥2,257,873,523.38, a reduction of 2.3%[20] - Total equity increased to ¥3,754,013,888.93 from ¥3,679,092,675.80, reflecting a growth of 2.0%[20] - Cash and cash equivalents at the end of the period are ¥1,019,112,530.43, up from ¥1,004,518,191.99 at the beginning of the period, indicating a growth of 1.5%[18] - Accounts receivable increased to ¥463,718,530.29 from ¥451,968,966.69, a rise of 2.0%[18] - Inventory increased to ¥75,126,345.90 from ¥59,719,225.77, representing a growth of 25.7%[18]

证券代码：301305 证券简称：朗坤环境 公告编号：2025-012 深圳市朗坤科技股份有限公司 享硕的基金管理人为广东华迪新能源环保投资有限公司，广东华迪投资集团有限 公司和广东华迪新能源环保投资有限公司受同一实际控制人控制。 2、股东持有公司股份情况 关于合计持股5%以上股东及其一致行动人减持股份预披露 公告 股东广州盛隆投资合伙企业（有限合伙）、贵州沛硕股权投资合伙企业（有 限合伙）和贵州享硕股权投资合伙企业（有限合伙）保证向本公司提供的信息内 容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 特别提示： 深圳市朗坤科技股份有限公司（以下简称"公司"或"发行人"）股东深圳 华迪光大股权投资基金（有限合伙）、广东千灯华迪股权投资企业（有限合伙）、 广州六脉资江股权投资合伙企业（有限合伙）、广州资江凯源股权投资合伙企业 （有限合伙）、广州盛隆投资合伙企业（有限合伙）（以下简称"广州盛隆"）、贵 州沛硕股权投资合伙企业（有限合伙）（以下简称"贵州沛硕"）和贵州享硕股权 投资合伙企业（有限合伙）（以下简称"贵州享硕"）具有一致行动关系 ...

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或者重大遗漏。 深圳市朗坤科技股份有限公司（以下简称"公司"）于 2024 年 4 月 17 日召 开第三届董事会第十六次会议、第三届监事会第八次会议，2024 年 5 月 10 日召 开 2023 年年度股东大会，审议通过了《关于使用部分闲置募集资金进行现金管 理的议案》。在不影响募集资金投资项目建设的情况下，使用总额不超过 5.65 亿 元的闲置募集资金（含超募资金）进行现金管理，购买包括但不限于结构性存款、 大额存单等安全性高、流动性好，期限最长不超过 12 个月（可转让大额存单除 外）的保本型理财产品。具体内容详见公司于 2024 年 4 月 19 日在巨潮资讯网 （http://www.cninfo.com.cn）披露的相关公告。 公司前期在徽商银行股份有限公司深圳龙岗支行开立了募集资金现金管理 专用结算账户，用于对部分闲置募集资金进行现金管理，具体内容详见公司于 2024 年 10 月 15 日在巨潮资讯网（http://www.cninfo.com.cn）披露的《关于开立 募集资金现金管理专用结算账户的公告》（公 ...

深圳市朗坤科技股份有限公司（以下简称"公司"）于 2024 年 4 月 17 日召 开第三届董事会第十六次会议、第三届监事会第八次会议，2024 年 5 月 10 日召 开 2023 年年度股东大会，审议通过了《关于使用部分闲置募集资金进行现金管 理的议案》。在不影响募集资金投资项目建设的情况下，使用总额不超过 5.65 亿 元的闲置募集资金（含超募资金）进行现金管理，购买包括但不限于结构性存款、 大额存单等安全性高、流动性好，期限最长不超过 12 个月（可转让大额存单除 外）的保本型理财产品。具体内容详见公司于 2024 年 4 月 19 日在巨潮资讯网 （http://www.cninfo.com.cn）披露的相关公告。 公司前期在广州银行股份有限公司白云支行开立了募集资金现金管理专用 结算账户，用于对部分闲置募集资金进行现金管理，具体内容详见公司于 2023 年 9 月 5 日在巨潮资讯网（http://www.cninfo.com.cn）披露的《关于开立募集资 金现金管理专用结算账户的公告》（公告编号：2023-035）。鉴于上述现金管理 专用结算账户相关的理财产品已到期赎回且无后续使用计划，公司已于 ...